Yttrium-90 radioembolization for unresectable, chemoresistant breast cancer liver metastases: a large single-center experience of 40 patients.
about
Current status of transarterial radioembolizationArterial Therapies of Non-Colorectal Liver MetastasesEffects of Yttrium-90 selective internal radiation therapy on non-conventional liver tumorsYttrium-90 microspheres: a review of its emerging clinical indicationsLocally ablative treatment of breast cancer liver metastases: identification of factors influencing survival (the Mammary Cancer Microtherapy and Interventional Approaches (MAMMA MIA) study)Metastatic Liver Disease: Indications for Locoregional Therapy and Supporting Data.Yttrium-90 radioembolization stops progression of targeted breast cancer liver metastases after failed chemotherapy.The value of intravoxel incoherent motion model-based diffusion-weighted imaging for outcome prediction in resin-based radioembolization of breast cancer liver metastases.Administered activity and outcomes of glass versus resin (90)Y microsphere radioembolization in patients with colorectal liver metastases.Yttrium-90 hepatic radioembolization: clinical review and current techniques in interventional radiology and personalized dosimetry.Beyond hepatocellular carcinoma and colorectal metastasis: the expanding applications of radioembolization.Making the Case: Intra-arterial Therapy for Less Common Metastases.Role of yttrium-90 in the management of unresectable hepatocellular carcinoma and hepatic metastases.Pretreatment albumin may aid in patient selection for intrahepatic Y-90 microsphere transarterial radioembolization (TARE) for malignancies of the liver.Safety of selective internal radiation therapy (SIRT) with yttrium-90 microspheres combined with systemic anticancer agents: expert consensus.
P2860
Q26744307-DC7BB1D3-F83B-403D-8A7A-A8004F5633BAQ26764990-971E89D4-F26C-4944-86B4-7E3837888697Q26799046-BB253426-E893-4D94-867A-DDC976F38745Q28083856-35C493A6-9920-47CD-88FE-FFAB1696DD47Q30657649-D1E31EDB-A7C2-4B3B-ABC0-ABF38684E2E7Q36392298-8CA5390C-E6FC-4035-89AF-0BD2F899BCB5Q36482781-49313F43-ED10-4832-81B6-D73366309811Q37082835-EBB11FF2-DBDE-47E6-A964-BC39469CA90BQ37131705-10557E51-7A5A-4EA2-99EC-D47E870A0759Q37601096-6A0CCC3F-497B-477E-8D46-48D5314C165BQ38225144-EEA108E3-4304-4FBC-B16C-D50DC57EEAF6Q38745186-66011589-033D-4A7A-BFFB-73E9B1BD3A87Q39761939-E67D24D6-03D9-4537-9192-DA75DAAB96D7Q47112804-8F0A7BB5-EFF2-4AF1-BBCB-7670136E31EEQ47134709-4861B55D-02ED-4B97-B147-A40E501A0FCC
P2860
Yttrium-90 radioembolization for unresectable, chemoresistant breast cancer liver metastases: a large single-center experience of 40 patients.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Yttrium-90 radioembolization f ...... ter experience of 40 patients.
@en
Yttrium-90 radioembolization f ...... ter experience of 40 patients.
@nl
type
label
Yttrium-90 radioembolization f ...... ter experience of 40 patients.
@en
Yttrium-90 radioembolization f ...... ter experience of 40 patients.
@nl
prefLabel
Yttrium-90 radioembolization f ...... ter experience of 40 patients.
@en
Yttrium-90 radioembolization f ...... ter experience of 40 patients.
@nl
P2093
P2860
P1476
Yttrium-90 radioembolization f ...... ter experience of 40 patients.
@en
P2093
Akshat Saxena
Baerbel Meteling
David L Morris
Jada Kapoor
Lourens Bester
P2860
P2888
P304
P356
10.1245/S10434-013-3436-1
P577
2013-12-15T00:00:00Z
P5875
P6179
1012352029